Details

Autor(en) / Beteiligte

• Pi-Sunyer, Xavier
• Astrup, Arne
• Fujioka, Ken
• Greenway, Frank
• Halpern, Alfredo
• Krempf, Michel
• Lau, David C.W
• le Roux, Carel W
• Violante Ortiz, Rafael
• Jensen, Christine Bjørn
• Wilding, John P.H

Titel

A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management

Ist Teil von

• The New England journal of medicine, 2015-07, Vol.373 (1), p.11-22

Ort / Verlag

United States: Massachusetts Medical Society

Erscheinungsjahr

2015

Quelle

MEDLINE

Beschreibungen/Notizen

• This trial compared once-daily liraglutide, a glucagon-like peptide-1 analogue, with placebo in overweight or obese patients. Liraglutide was associated with clinically meaningful weight loss, a decrease in glycemia and risk factors, and improvement in quality of life. The increase in the rate of obesity, a chronic disease with serious health consequences, largely explains the recent tripling in the prevalence of type 2 diabetes. 1 , 2 Weight loss of 5 to 10% has been shown to reduce complications related to obesity and improve quality of life 3 – 7 ; however, weight loss is difficult to maintain with lifestyle intervention alone. 8 Liraglutide, a glucagon-like peptide-1 analogue with 97% homology to human glucagon-like peptide-1, is approved for the treatment of type 2 diabetes at doses up to 1.8 mg once daily. 9 Weight loss with liraglutide is dose-dependent up to 3.0 mg once . . .